Sentences with phrase «for ovarian cancer patient»

The targeted antibody bevacizumab (Avastin ®) is already approved for ovarian cancer patients, and a number of immune - based therapies are being investigated in early - phase clinical trials for patients with ovarian cancer.

This is desperately needed for ovarian cancer patients,» Wilkinson - Ryan explains.

We also work with oncologists and other doctors who understand the severity and life - risks for ovarian cancer patients.

Not exact matches

In a 564 - person trial, patients whose ovarian cancer recurred (and who had already started treatment with chemotherapy) given Rubraca, part of a new class of cancer drugs called «PARP» inhibitors, lived, on median, for double the amount of time without their disease getting even worse compared with those given a placebo.

Nanotax works by flipping the script on how paclitaxel is administered to patients and with how it's formulated, potentially making it a more effective and better tolerated treatment for ovarian and other abdominal cancers.

Paclitaxel and another chemotherapy drug, carboplatin, are considered standard, first - line treatments for advanced ovarian cancer, experts say, and most patients respond to the drugs initially.

Frequent shots of the MIS protein are too expensive for broad use, but they could help protect the reserve of ovarian follicles in young cancer patients.

«For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer.&raqFor this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer.&raqfor treating certain patients with ovarian cancer.»

Another study, conducted by Barbara Weber and her colleagues at the University of Pennsylvania, screened 263 breast cancer patients for BRCA1 mutations and asked them about their family history of breast and ovarian cancers.

The study, which compared each model's success in Caucasian women with those of Asian descent (Chinese, Japanese, Filipino, Korean and Vietnamese), also raised important questions about the effect of race on cancer development: When Caucasian and Asian patients with similar family histories of breast and ovarian cancer were compared, the Asian women had higher rates of genetic mutation, although the rates of these cancers for Asians have traditionally been lower.

«We know that patients with BRCA mutations are at high risk for developing breast, as well as pancreatic, ovarian, prostate and other cancers, and we have learned over time that BRCA plays a very important role in DNA damage repair.

Clinical trials of treatments for ovarian and related cancers would benefit from knowledge of patients» gene mutations, but in many trials, the cost of genetic testing is prohibitively expensive, the brief says.

For instance, a plaintiff in the Supreme Court case, Ellen T. Matloff of Yale Cancer Center, said that in 2006 she knew of a patient who had had breast and ovarian cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York TimFor instance, a plaintiff in the Supreme Court case, Ellen T. Matloff of Yale Cancer Center, said that in 2006 she knew of a patient who had had breast and ovarian cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York Cancer Center, said that in 2006 she knew of a patient who had had breast and ovarian cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York cancer who tested negative for BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York Timfor BRCA1 and BRCA2, suggesting that this patient's cancers were not the result of a hereditary condition, according to the New York Times.

Nagrath, director of Rice's Laboratory for Systems Biology of Human Diseases, said the new metabolic analysis indicates that ovarian cancer may be susceptible to multidrug cocktails, particularly if the amounts of the drugs can be tailored to match the metabolic profile of a patient's tumor.

Dr. Tordjman and her colleagues studied the effect of radioactive iodine treatment on the ovarian reserve of women treated for differentiated thyroid cancer (DTC) by measuring their blood levels of anti-Müllerian hormone (AMH) and following the patients for up to one year after treatment.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: «Although we're making great progress, we still have more to do for people with ovarian cancer, as only one in three patients survive for 10 years or lCancer Research UK's chief clinician, said: «Although we're making great progress, we still have more to do for people with ovarian cancer, as only one in three patients survive for 10 years or lcancer, as only one in three patients survive for 10 years or longer.

This test may be particularly useful for patients with high grade serous ovarian cancer because the mutated cancer gene TP53 is found in more than 99 per cent of patients with this form of the disease.

Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer.

Researchers are also studying ovarian tissue transplantation for patients with cancer.

Studies have shown that ovarian cancer patients have a better chance of survival if they are referred to a specialized gynaecological cancer unit, but this only happens for a minority of women in Europe and the US at present.

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves — despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

«One in five women with ovarian cancer does not undergo surgery, study reveals: Results show survival benefit of surgery for patients regardless of age or advanced disease, and point to barriers to cancer care delivery.»

The researchers also are seeking other potential drug targets in the 50 percent of patients who don't have high levels of the anti-death protein, as well as biomarkers in addition to CA125 that could be used to screen for ovarian cancer.

Sood and colleagues looked at samples from 80 cases of human ovarian cancer grouped according to patient stress using the National Institutes of Health's Center for Epidemiological Studies Depression scale as a surrogate marker.

«If studies in larger groups of women confirm our finding that the fallopian tubes are the site of origin of most ovarian cancer, then this could result in a major change in the way we manage this disease for patients at risk.»

• Diagnostic laparoscopy for all surgically fit patients with suspected advanced - stage ovarian cancer.

«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).

«We are looking forward to further exploring this combination in ovarian cancer and potentially increasing effective treatment options for our patients with this cancer.»

Based on these results, two phase 3 trials are being planned for platinum - sensitive and platinum - resistant ovarian cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group cancer patients by one of NCI's new National Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group Cancer Trial Network Groups, the NRG Oncology Group (formerly 3 cooperative groups: the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG).

Longer term, they want to quickly diagnose additional cancer types, including ovarian and pancreatic cancers, which are fast - spreading and require early detection for a patient to survive, says Goda, who was recently appointed as a chemistry professor at the University of Tokyo but will continue his research with U.C.L.A..

He concluded: «Once it is approved by the regulatory authorities, I'll consider niraparib for all my patients with recurrent ovarian cancer who respond to platinum regardless of BRCA status.»

The drugs are already approved for treatment of patients with advanced breast cancer as well as ovarian, pancreatic and certain lung cancers.

But so far in trials for ovarian cancer they have blocked tumor growth in many patients, Levine notes.

Now a new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thCancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thcancer is likely to respond to checkpoint inhibitor therapy.

Go to our Cancer Immunotherapy Clinical Trial Finder to find clinical trials of immunotherapies for ovarian cancer that are currently enrolling patCancer Immunotherapy Clinical Trial Finder to find clinical trials of immunotherapies for ovarian cancer that are currently enrolling patcancer that are currently enrolling patients.

Together, these and other findings strongly suggest that immunotherapies that can induce or enhance optimal immunologic conditions within ovarian cancers may hold great promise for extending the lives of ovarian cancer patients.

Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.

The poor survival in advanced ovarian cancer is due both to late diagnosis, as well as to the lack of effective second - line therapy for patients who relapse.

First - line treatment for ovarian cancer includes surgery followed by a chemotherapy regimen combining a platinum - based (usually carboplatin) and a taxane - based (usually paclitaxel) treatment, which achieves a complete response in approximately 80 % of patients.

Several phase I and II trials of adoptive T cell transfer techniques are currently under way for patients with ovarian cancer, including:

Through CRI's Clinical Accelerator program, two new checkpoint inhibitor drugs, MEDI4736 (anti-PD-L1) and tremelimumab (anti-CTLA-4), are being tested in a phase I trial for patients with six different cancer types, including colorectal cancer, cervical cancer, head and neck cancer, kidney cancer, lung cancer, and ovarian cancer.

$ 1.8 M Supports Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed Use among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization of Pediatric Stem Cell Transplant Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways in the Development of Ovarian Cancer GMNews.com - March 2, 2016 Differences in Type of Small Protein may further Elucidate Lung Cancer Risk in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the Line on Tanning Bed Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette Use NJBiz.com - December 9, 2015 Identification of Barrier that Prevents Progression of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color of the Lung Cancer Ribbon?

This raises the exciting possibility that therapies for ovarian cancer might benefit patients with Basal breast tumors, and vice-versa.

Cancer Network: What are the ways to test for this deficiency of homologous recombination in patients with ovarian cCancer Network: What are the ways to test for this deficiency of homologous recombination in patients with ovarian cancercancer?

«Both the efficacy and safety results from the ARIEL3 study reinforce the important role of Rubraca in the treatment of recurrent ovarian cancer and expands the treatment options for patients and physicians battling this disease,» he said.

Doctors often fail to recommend genetic testing for breast - cancer patients, even those who are at high risk for mutations linked to ovarian and other cancers, according to a study published Tuesday.

In addition, drugs called PARP inhibitors, which have been shown to benefit some ovarian cancer patients with BRCA mutations, may be of use for prostate cancer patients with the gene defects.

Coukos, who is currently leading an ovarian cancer clinical trial sponsored by CRI's Clinical Accelerator, sought to understand why PD - 1 / PD - L1 immunotherapies are often ineffective for these patients, even though ovarian tumors are often infiltrated by «killer» T cells that recognize tumor - specific neoantigens and express high levels of PD - 1.

ZEJULA is the first and only once - daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.1 - 3

ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.